ArticleScientific reports2026
Designing of a conserved subunit multiepitope vaccine candidate against Francisella tularensis Schu S4 using immunoinformatics.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Francisella tularensis Schu S4 is the most virulent strain responsible for tularemia, a highly infectious zoonotic disease. Despite its potential as a pathogen of concern, no effective vaccine has been developed for this pathogen. In this study, two multi-epitope subunit vaccine candidates were designed targeting the virulence factors DacD and DsbA to reduce disease severity caused by F. tularensis Schu S4. Using a comprehensive immunoinformatics approach, the most efficient B- and T-cell epitopes were identified from conserved sequences and linked with adjuvants and linkers to generate two vaccine constructs. These constructs were modeled, refined, and validated through molecular docking against Toll-Like Receptors (TLRs) and MHC alleles, followed by 200 ns molecular dynamics simulations. Their immunogenic potential and expression efficiency were further evaluated through immune simulations and computational cloning into the pET30a( +) vector. Both the constructed vaccine candidates, TulaVac1 and TulaVac2, showed high antigenicity, immunogenicity, stability, and solubility. The epitope conservancy was nearly 100%, with global population coverage rates of 73.19% and 99.74% for MHC class I and II epitopes, respectively. Docking analyses revealed six CTL epitopes with binding energies of ≤ -9.0 kcal/mol, while vaccine-TLR and MHC docking suggested superior performance of TulaVac1. MM/GBSA analysis yielded favorable binding energies ranging from - 87.22 to - 161.30 kcal/mol, MD simulations confirmed the stable interaction for 200 ns, and immune simulations showed robust immune responses with satisfactory codon adaptation. These findings position TulaVac1 and TulaVac2 as promising candidates for effective prophylaxis against tularemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.